Merck & Co Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Merck & Co Inc Unternehmen

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

Merck & Co Inc Informationen



BörsenkürzelMRK

Name des UnternehmensMerck & Co Inc

IPO-datumJan 01, 1941

CEOMr. Robert M. (Rob) Davis

Anzahl der mitarbeiter75000

WertpapierartOrdinary Share

GeschäftsjahresendeJan 01

Addresse126 East Lincoln Avenue

StadtRAHWAY

BörseNYSE Consolidated

LandUnited States of America

Postleitzahl07065

Telefon19087404000

Websitehttps://www.merck.com/

BörsenkürzelMRK

IPO-datumJan 01, 1941

CEOMr. Robert M. (Rob) Davis

Führungskräfte von Merck & Co Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

--

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

85.34K

+28.11%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

79.59K

+0.92%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

53.42K

+90.81%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

22.91K

+5.27%

Ms. Patricia F. Russo

Independent Director

13.15K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

--

Mr. Inge G. Thulin

Independent Director

2.93K

--

Ms. Pamela J. Craig

Independent Director

1.72K

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

--

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

85.34K

+28.11%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

79.59K

+0.92%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel

53.42K

+90.81%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

22.91K

+5.27%

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Oncology-Keytruda

7.96B

50.34%

Vaccines -Gardasil/Gardasil

1.13B

7.12%

Animal Health-Livestock

961.00M

6.08%

Animal Health-Companion Animals

685.00M

4.33%

Vaccines -ProQuad/M-M-R II/Varivax

609.00M

3.85%

Andere

4.47B

28.27%

Nach RegionUSD

Name

Umsatz

Anteil

United States

8.84B

55.90%

Europe, Middle East and Africa

3.66B

23.15%

Latin America

859.00M

5.43%

Asia Pacific (Other than China and Japan)

785.00M

4.97%

Japan

626.00M

3.96%

Andere

1.04B

6.59%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Oncology-Keytruda

7.96B

50.34%

Vaccines -Gardasil/Gardasil

1.13B

7.12%

Animal Health-Livestock

961.00M

6.08%

Animal Health-Companion Animals

685.00M

4.33%

Vaccines -ProQuad/M-M-R II/Varivax

609.00M

3.85%

Andere

4.47B

28.27%

Aktionärsstatistik

Aktualisiert: Tue, Aug 19

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

10.11%

BlackRock Institutional Trust Company, N.A.

5.75%

State Street Investment Management (US)

4.77%

Wellington Management Company, LLP

3.10%

Geode Capital Management, L.L.C.

2.38%

Andere

73.89%

Aktionäre

Anteil

The Vanguard Group, Inc.

10.11%

BlackRock Institutional Trust Company, N.A.

5.75%

State Street Investment Management (US)

4.77%

Wellington Management Company, LLP

3.10%

Geode Capital Management, L.L.C.

2.38%

Andere

73.89%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

42.33%

Investment Advisor/Hedge Fund

27.33%

Research Firm

3.24%

Pension Fund

2.47%

Bank and Trust

2.34%

Sovereign Wealth Fund

1.56%

Hedge Fund

1.38%

Insurance Company

0.71%

Family Office

0.12%

Andere

18.53%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

5358

2.02B

81.35%

-45.75M

2025Q2

5398

2.02B

80.82%

-16.42M

2025Q1

5446

2.05B

81.47%

-3.32M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

2023Q3

4871

1.98B

78.17%

-32.03M

2023Q2

4864

2.00B

78.94%

-18.54M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

251.75M

10.08%

+356.59K

+0.14%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

142.78M

5.72%

-4.51M

-3.06%

Jun 30, 2025

State Street Investment Management (US)

118.49M

4.74%

-2.04M

-1.69%

Jun 30, 2025

Wellington Management Company, LLP

76.86M

3.08%

-4.81M

-5.89%

Jun 30, 2025

Geode Capital Management, L.L.C.

58.95M

2.36%

-704.59K

-1.18%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

53.87M

2.16%

+4.64M

+9.42%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

36.11M

1.45%

+1.13M

+3.23%

Jun 30, 2025

Fidelity Management & Research Company LLC

28.48M

1.14%

+229.47K

+0.81%

Jun 30, 2025

Fisher Investments

25.01M

1%

+567.90K

+2.32%

Jun 30, 2025

BlackRock Asset Management Ireland Limited

22.79M

0.91%

+764.14K

+3.47%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

FT Vest DJIA Dogs 10 Target Income ETF

7.58%

VanEck Pharmaceutical ETF

7.44%

First Trust NASDAQ Pharmaceuticals ETF

7.32%

Coastal Compass 100 ETF

7.15%

Invesco Dow Jones Industrial Average Dividend ETF

6.85%

iShares ESG Aware MSCI USA Value ETF

5.44%

First Trust Morningstar Dividend Leaders Index Fund

5.03%

Franklin Income Focus ETF

4.92%

Invesco Pharmaceuticals ETF

4.84%

VanEck Morningstar Wide Moat Value ETF

4.6%

FT Vest DJIA Dogs 10 Target Income ETF

Anteil7.58%

VanEck Pharmaceutical ETF

Anteil7.44%

First Trust NASDAQ Pharmaceuticals ETF

Anteil7.32%

Coastal Compass 100 ETF

Anteil7.15%

Invesco Dow Jones Industrial Average Dividend ETF

Anteil6.85%

iShares ESG Aware MSCI USA Value ETF

Anteil5.44%

First Trust Morningstar Dividend Leaders Index Fund

Anteil5.03%

Franklin Income Focus ETF

Anteil4.92%

Invesco Pharmaceuticals ETF

Anteil4.84%

VanEck Morningstar Wide Moat Value ETF

Anteil4.6%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 35.12B USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Jul 25, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Oct 06, 2023

Sep 14, 2023

May 23, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jul 10, 2023

Jun 14, 2023

Jan 24, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Apr 10, 2023

Mar 14, 2023

Nov 30, 2022

MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022

Dec 15, 2022

Jan 09, 2023

Dec 14, 2022

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten